Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/23830974/ below:

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study

Affiliations

• ¹ SP-POS, Centre de recherche du CHU de Québec, Québec, Canada. marc.brisson@uresp.ulaval.ca

• PMID: 23830974
• DOI: 10.1016/j.vaccine.2013.06.064

Item in Clipboard

Marc Brisson et al. Vaccine. 2013.

• ¹ SP-POS, Centre de recherche du CHU de Québec, Québec, Canada. marc.brisson@uresp.ulaval.ca

• PMID: 23830974
• DOI: 10.1016/j.vaccine.2013.06.064

Item in Clipboard

Background: The quadrivalent and bivalent human papillomavirus (HPV) vaccines are now licensed in several countries. We compared the cost-effectiveness of the HPV vaccines to provide evidence for policy decisions.

Methods: We developed HPV-ADVISE, a multi-type individual-based transmission-dynamic model of HPV infection and disease (anogenital warts, and cervical, anogenital and oropharyngeal cancers). We calibrated the model to sexual behavior and epidemiologic data from Canada, and estimated quality-adjusted life-years (QALYs) lost and costs ($CAN 2010) from the literature. Vaccine-type efficacy was based on a systematic literature review. The analysis was performed from the healthcare provider perspective, and costs and benefits were discounted at 3%. Predictions are presented using the median [10th;90th percentiles] of simulations.

Results: Under base-case assumptions (vaccinating 10-year-old girls, 80% coverage, $95/dose), using the quadrivalent and bivalent vaccines is estimated to cost $15,528 [12,056;19,140] and $20,182 [15,531;25,240] per QALY-gained, respectively. At equal price, the quadrivalent vaccine is more cost-effective than bivalent under all scenarios investigated, except when assuming longer duration of protection for the bivalent and minimal anogenital warts burden. Under base-case assumptions, the maximum additional cost per dose for the quadrivalent vaccine to remain more cost-effective than the bivalent is $32 [17;46] (using a $40,000/QALY-gained threshold). Results were most sensitive to discounting, time-horizon, differences in durations of protection and anogenital warts burden.

Conclusions: Vaccinating pre-adolescent girls against HPV is predicted to be highly cost-effective. If equally priced, the quadrivalent is the most economically desirable vaccine. However, ultimately, the most cost-effective HPV vaccine will be determined by their relative price.

Keywords: Cervical cancer; Cost-effectiveness; Economic analysis; HPV vaccination; Mathematical modeling.

Copyright © 2013 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

• Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

  Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC, Markowitz LE. Brisson M, et al. J Natl Cancer Inst. 2015 Oct 4;108(1):djv282. doi: 10.1093/jnci/djv282. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26438574 Free PMC article.

• Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.

  Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M. Drolet M, et al. Int J Cancer. 2014 May 1;134(9):2264-8. doi: 10.1002/ijc.28541. Epub 2013 Oct 31. Int J Cancer. 2014. PMID: 24174175

• Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

  Demarteau N, Van Kriekinge G, Simon P. Demarteau N, et al. Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15. Vaccine. 2013. PMID: 23777952

• Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.

  Armstrong EP. Armstrong EP. J Manag Care Pharm. 2010 Apr;16(3):217-30. doi: 10.18553/jmcp.2010.16.3.217. J Manag Care Pharm. 2010. PMID: 20331326 Free PMC article. Review.

• Prevention strategies against the human papillomavirus: the effectiveness of vaccination.

  Stanley M. Stanley M. Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S19-23. doi: 10.1016/j.ygyno.2007.07.068. Gynecol Oncol. 2007. PMID: 17938013 Review.

• Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis.

  Drolet M, Laprise JF, Chamberland É, Sauvageau C, Wilson S, Lim GH, Ogilvie G, Tuite A, Brisson M. Drolet M, et al. CMAJ. 2024 Oct 6;196(33):E1136-E1143. doi: 10.1503/cmaj.240787. CMAJ. 2024. PMID: 39374971 Free PMC article.

• HPV vaccination in India.

  Palefsky J. Palefsky J. South Asian J Cancer. 2014 Jan;3(1):93-4. doi: 10.4103/2278-330X.126577. South Asian J Cancer. 2014. PMID: 24665458 Free PMC article. No abstract available.

• Gender-Neutral HPV Vaccine in India; Requisite for a Healthy Community: A Review.

  Kaur KN, Niazi F, Nandi D, Taneja N. Kaur KN, et al. Cancer Control. 2024 Jan-Dec;31:10732748241285184. doi: 10.1177/10732748241285184. Cancer Control. 2024. PMID: 39344048 Free PMC article. Review.

• Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

  Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC, Markowitz LE. Brisson M, et al. J Natl Cancer Inst. 2015 Oct 4;108(1):djv282. doi: 10.1093/jnci/djv282. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26438574 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3